Bora Pharmaceuticals partners with Celltrion to crack the APAC market

Bora Pharmaceuticals facility in Zhunan, Taiwan

Bora Pharmaceuticals, the international cGMP CDMO producing specialised pharmaceutical products such as sterile and non-sterile ophthalmics and nasal sprays for clinical use, is partnering with Celltrion Asia Pacific, subsidiary of Celltrion Group Inc.

The range of products they will be taking to the APAC market will be oral dosage form products that have been manufactured at Bora Pharmaceutical’s manufacturing site in Zhunan, Taiwan. The site is one of the largest in Taiwan with full US FDA and MHRA-approved pharmaceutical production facilities and has an exemplary compliance record with global regulatory authorities. 

Celltrion is a biopharmaceutical company based in Incheon, South Korea, that focuses on the research, development, and manufacture of innovative therapeutics such as monoclonal antibody biosimilars. Bora’s manufacturing capabilities will add to Celltrion’s offering by supporting Celltrion’s pitch for regulatory approval in seven new countries as well as aiding in the rapid commercialisation of it’s products. 

Bobby Sheng, CEO and Chairman of Bora, commented: “We are extremely excited about this new partnership with Celltrion. As a trusted global partner, we look forward to serving our customers with the best technical and quality resources and supporting our partners to expand into various markets around the world.”